A multicenter, double-blind, randomized, parallel group, positive-controlled trial comparing the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral b.i.d. [twice daily] to carabamazepine (400 to 1200 mg/day oral b.i.d.), used as monotherapy for up to a maximum of 121 weeks in subjects (greater than or equal to 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Levetiracetam (Primary) ; Carbamazepine
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Registrational; Therapeutic Use
- Sponsors UCB Pharma Inc
- 10 Oct 2006 Status change
- 13 Nov 2005 New trial record.